Traders Speculate Circulation Of Tweet Of Ocular Therapeutix Presentation Today At AAO; Shares Spike Higher
https://twitter.com/buysidebio/status/1575568356823822336
Ocular Therapeutix’s Wet AMD Candidate Shows Sustained, Comparable Clinical Activity Vs. Eylea
Ocular Therapeutix Inc (NASDAQ:OCUL) announced interim 7-month data from its U.S. Phase 1 trial evaluating OTX-TKI for wet age-related macular degeneration…
Ocular Therapeutix Announced Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD; Said 80% of Subjects were Rescue-Free up to 6 months and 73% of Subjects Were Rescue-Free up to 7 months Following a Single OTX-…
Ocular Therapeutix, Inc. (NASDAQ: OCUL) today announced interim 7-month data from its U.S. Phase 1 clinical trial evaluating OTX-TKI, the Company's axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases.
Why Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket
Gainers
Spero Therapeutics, Inc. (NASDAQ: SPRO) rose 105.6% to $1.69 in pre-market trading. GSK and Spero Therapeutics announced exclusive license agreement for late-stage antibiotic asset, Tebipenem HBr.